2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
38 citations
,
September 2017 in “Journal of zoo and wildlife medicine” Oclacitinib maleate successfully treated alopecia in Andean bears.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia” 2 citations
,
January 2017 in “Ciência Rural” A capuchin monkey with a skin infection was successfully treated with itraconazole.
22 citations
,
March 2017 in “Transplant Infectious Disease” Leflunomide successfully treated a rare skin condition in a liver transplant patient.
January 2024 in “Journal of the American Academy of Dermatology” Gabapentin helps with scalp itch, dutasteride works for frontal fibrosing alopecia, and more research is needed for better PCA treatments.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
March 2005 in “European Urology Supplements” 1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical Vorinostat shows promise for treating alopecia areata by promoting hair regrowth.
11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology”
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
2 citations
,
April 2019 in “Journal of the American Society of Nephrology” Fluconazole might be a new treatment for a type of diabetes that affects water balance in the body.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
3 citations
,
February 2024 in “Journal of the American Academy of Dermatology” Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Five FDA-approved drugs may help block COVID-19 virus entry.
July 2024 in “Reactions Weekly”
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.